STAAR Surgical Company (STAA)
$
17.63
-0.16 (-0.91%)
Key metrics
Financial statements
Free cash flow per share
0.2030
Market cap
861.2 Million
Price to sales ratio
2.7436
Debt to equity
0.0975
Current ratio
5.2334
Income quality
-0.7782
Average inventory
20.2 Million
ROE
0.0455
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
STAAR Surgical Company, along with its subsidiaries, is engaged in the design, development, manufacturing, marketing, and sale of implantable lenses tailored for the eye, along with companion delivery systems to facilitate lens implantation. The company’s Visian implantable Collamer lens product line (ICLs) addresses a variety of visual disorders including myopia, hyperopia, astigmatism, and presbyopia, while its Hyperopic ICL specifically targets far-sightedness. Furthermore, STAAR provides preloaded silicone intraocular lenses for cataract surgeries, alongside injector systems. It also distributes injector components and related instruments and devices. The company markets these offerings primarily to healthcare providers such as ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, with a strong focus on ophthalmologists. STAAR’s sales operations are conducted directly through its representatives across various countries including the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In addition, sales are executed through independent distributors and its own representatives in markets ranging from China and Korea to India, France, Benelux, and Italy. STAAR Surgical Company has shown a net income of -$20,208.00 reflecting its profitability. The net income ratio is 0.00 underscoring the company’s profitability margin. Additionally, the company has incurred an interest expense of $0.00 indicating its debt servicing obligations. The operating income ratio stands at -0.04 illustrating the company's operational profitability, while the income before tax ratio is -0.03 which highlights its pre-tax margin. The stock is affordable at $17.57 making it an attractive option for budget-conscious investors. With a market capitalization of $869,606,802.00 the company is categorized as a small-cap player. It operates within the Medical - Instruments & Supplies industry, where it plays a key role in shaping the overall market landscape and contributing to industry advancements. The stock exhibits an average trading volume of 1,087,666.00 suggesting moderate liquidity, and it belongs to the Healthcare sector, where it continues to drive innovation and growth.
What is STAAR Surgical Company (STAA)'s stock forecast?
Analysts predict STAAR Surgical Company stock to fluctuate between $13.50 (low) and $52.68 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is STAAR Surgical Company's market capitalization?
As of 2025-04-01, STAAR Surgical Company's market cap is $869,606,802, based on 49,325,400 outstanding shares.
How does STAAR Surgical Company compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., STAAR Surgical Company has a Lower Market-Cap, indicating a difference in performance.
How can I buy STAAR Surgical Company (STAA) stock?
To buy STAAR Surgical Company (STAA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STAA. Place an order (Market, Limit, etc.).
What is the best time to invest in STAAR Surgical Company?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did STAAR Surgical Company perform in the last earnings report?
Revenue: $313,901,000 | EPS: -$0.41 | Growth: -193.18%.
Where can I find STAAR Surgical Company's investor relations reports?
Visit https://www.staar.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for STAAR Surgical Company?
You can explore historical data from here
What is the all-time high and low for STAAR Surgical Company stock?
All-time high: $163.08 (2021-09-07) | All-time low: $13.50 (2025-02-12).
What are the key trends affecting STAAR Surgical Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures.
prnewswire.com
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures.
See all news
